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Summary Statement:  We report 14 consecutive cases of sterile 
endophthalmitis after intravitreal injection of bevacizumab obtained from a single 
batch.  Ocular pain, hyperemia, cellular infiltration, and vitreous opacity 
appeared a few days after the injection.  Most eyes regained initial visual acuity 
after treatment, which included pars plana vitrectomy in some cases. 
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Purpose:  To report 14 consecutive cases of endophthalmitis after intravitreal 
injection of bevacizumab obtained from a single batch. 
Methods:  One vial of bevacizumab (100 mg/4 ml) was divided into 20 sterile 
injections and kept at 4ºC before use.  Bevacizumab (1.25 mg/0.05 ml) was 
injected intravitreally into 19 eyes of 15 patients to treat macular edema or 
choroidal neovascularization.  All treatments were performed within 1 week of 
the bevacizumab, which was from a single batch, being aliquotted into the 20 
doses. 
Results:  Of the 19 eyes, 14 showed moderate to severe ocular inflammation 
shortly after injection.  Cultures of aqueous humor and vitreous from 5 eyes 
were negative for bacteria and fungi.  Eyes with moderate inflammation 
received topical or systemic antibiotics and steroid treatment.  Five eyes with 
severe inflammation underwent pars plana vitrectomy because of dense vitreous 
opacity.  Visual acuity returned to pre-endophthalmitis levels in 12 eyes but had 
declined in 2 eyes at one month after the injection. 
Conclusions:  Intravitreal injection of bevacizumab can cause sterile 
endophthalmitis.  Most inflammation occurred within a few days after the 
intravitreous injection of the bevacizumab, but treatment with antibiotics, steroids, 
and/or vitrectomy was effective, and the prognosis was good in most cases. 
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Bevacizumab (Avastin, Roche, Basel, Switzerland) is a recombinant 
humanized monoclonal antibody against vascular endothelial growth factor that 
was developed originally to treat metastatic carcinoma of the colon and rectum.1  
Because it was designed to be used systemically, Michels and colleagues used 
off-label bevacizumab intravenous infusions to treat neovascular age-related 
macular degeneration (AMD).2  After the efficacy of intravenous bevacizumab 
on AMD was proved, it was administered intravitreally,3, 4 and injection of 
intravitreous bevacizumab (IVB) began to be used widely for treatment of 
various ocular diseases, including branch retinal vein occlusion (BRVO),5, 6 
polypoidal choroidal vasculopathy (PCV),7, 8 retinal angiomatous proliferation 
(RAP),9, 10 myopic choroidal neovascularization (CNV),11, 12 CNV secondary to 
angioid streaks (AS),13, 14 proliferative diabetic retinopathy,15, 16 and neovascular 
glaucoma.17, 18 
IVB can cause complications, including traumatic cataract, retinal 
detachment, and endophthalmitis, with the reported incidence of endophthalmitis 
ranging from 0.014% to 0.082%.19-24  Although several cases of sterile 
endophthalmitis have been reported, most of these cases have been sporadic 
and in most instances the inflammation subsided with no treatment or with 
topical treatment.4, 25-27 
In late December 2008, Genentech issued a letter informing 
ophthalmologists about 36 cases of intraocular adverse reactions following the 
off-label use of intravitreal bevacizumab.  Most cases that have been reported 
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occurred in patients who received intravitreal bevacizumab from a single batch.  
However, the precise ocular symptoms, reaction to the treatment, and visual 
prognosis have not been reported. 
In the present study, we describe 14 consecutive cases of sterile 
endophthalmitis after injection of IVB, some of which required pars plana 
vitrectomy.  Each of these 14 eyes was treated with bevacizumab that 
originated from a single batch. 
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Patients and Methods 
 
The current study was approved by the Institutional Review Board at 
Kyoto University Graduate School of Medicine, and all investigations adhered to 
the tenets of the Declaration of Helsinki. 
 Commercially available bevacizumab (100 mg/4 ml) was aliquotted into 
smaller doses (5 mg/0.2 ml x 20) under sterile conditions by the pharmacy unit 
and maintained at 4 ºC for less than a week prior to use.  Intravitreal 
bevacizumab (1.25 mg/0.05 ml) was injected into nineteen eyes of fifteen 
patients: three eyes of three patients with BRVO, six eyes of five patients with 
AMD, two eyes of two patients with PCV, three eyes of two patients with RAP, 
three eyes of two patients with myopic CNV, and two eyes of one patient with 
CNV secondary to AS (Table 1).  Each of these patients received IVB within one 
week of the bevacizumab being aliquotted from a single vial.  Triamcinolone 
acetonide was intravitreously injected with the bevacizumab in two eyes, and 
photodynamic therapy was performed three days after the bevacizumab 
injection in three eyes.  The average age of the 15 patients was 77.3 ± 9.1 
years.  Previous treatment with intravitreal bevacizumab had been performed in 
12 eyes (63.2%). 
All patients used antibiotic eye drops (gatifloxacin) for a week before 
the IVB treatment.  After topical anesthesia, the eye and the lids were 
disinfected.  Bevacizumab was injected into the vitreous cavity at a distance of 
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3.5-4.0 mm posterior to the corneal limbus with a 30-gauge needle.  The 
injection site was compressed for one minute with a cotton swab to avoid reflux 
when the needle was withdrawn.  Patients were directed to use the antibiotic 
eye drops (gatifloxacin) for an additional week after the injection of IVB. 
      All values are presented as mean ± SD.  The data were analyzed by 
Fisher's exact test.  Measurement values of three groups were compared using 
analysis of variance with post hoc comparisons tested by the Scheffe procedure.  
P values of less than 0.05 were considered to be statistically significant 
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Results 
 
Ocular inflammation occurred in 14 eyes of 11 patients a few days after 
IVB injection (Tables 1 and 2), while the other 5 eyes did not show any 
inflammatory sign after receiving the IVB.  The vitreous opacity became so 
dense that the optic disc could be observed only barely in 5 eyes, which were 
classified as the "severe inflammation" group; the other 11 eyes with 
inflammation were classified as the "moderate inflammation" group.  The 5 
eyes without inflammation were classified as the "no inflammation" group. 
In eyes with severe ocular inflammation, the patients complained of eye 
pain and moderate conjunctival hyperemia.  Slitlamp examination revealed 
moderate to severe cellular infiltration in the anterior chamber and vitreous 
cavity; three eyes showed hypopyon.  The vitreous opacity became extensively 
dense in spite of intravenous antibiotics (imipenem), and visual acuity declined 
to count fingers in two eyes, to 2.0 in logMAR in two eyes, and to 1.5 in logMAR 
in one eye.  These five eyes with severe ocular inflammation underwent pars 
plana vitrectomy (PPV) with instillation of intravitreal antibiotics (vancomycin and 
ceftazidime) on the third day; a sample of aqueous humor and vitreous was 
collected for culture.  These cultures were all negative for Gram-positive 
bacteria, Gram-negative bacteria, and fungi. 
Eyes with moderate ocular inflammation were treated with topical 
antibiotics (gatifloxacin and cefmenoxime) with or without a topical steroid 
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(betamethasone).  In the two eyes with moderate vitreous opacity, systemic 
antibiotics (cefotiam) and a steroid (predonizolone) were added to the topical 
treatment.  The inflammatory reaction in the anterior segment subsided within 
one week and the vitreous opacity subsided within a month.  Some of the eyes 
thought to have no inflammation were not examined for several days after 
having been seen on the day after IVB injection, so ocular inflammation may 
have been present for a few days, without consultation, in these eyes. 
Each patient was followed-up for at least one month after IVB treatment.  
Visual acuity was unchanged from pretreatment levels in 17 eyes but declined in 
2 (Figure); it was restored to the level before IVB injection in the "no 
inflammation" group and in the "moderate inflammation" group, but declined in 
two eyes in the "severe inflammation" group. 
A previous intravitreal injection of bevacizumab had been given 0.80 ± 
0.84 times in the "no inflammation" group, 1.67 ± 1.87 times in the "moderate 
inflammation" group, and 2.20 ± 2.17 times in the "severe inflammation" group, 
so there was no significant difference in the frequency of a prior IVB injection (P 
= 0.46).  Furthermore, there was no significant difference when the experience 
was compared among the three groups: two eyes without prior IVB and three 
eyes with prior IVB in the "no inflammation" group, four eyes without prior IVB 
and five eyes with prior IVB in the "moderate inflammation" group, and one eye 
without prior IVB and four eyes with prior IVB in the "severe inflammation" group.  
No inflammatory reaction was detected after any of these previous IVB 
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injections. 
Cataract surgery had been performed in one eye (20%) in the "no 
inflammation" group, in three eyes (33%) in the"moderate inflammation" group, 
and in four eyes (80%) in the "severe inflammation" group, so there was no 




This representative patient was an 82-year-old female with CNV secondary to 
high myopia; axial length was 32.0 mm in each eye.  Her left eye had been 
treated previously three times with IVB.  Since new CNV had developed in each 
eye, she had received intravitreal injections of 1.25 mg bevacizumab in each eye, 
with an interval of 3 months.  On the day following the second injection, she 
noted moderate ocular pain and conjunctival hyperemia in both eyes.  Slitlamp 
examination revealed moderate cellular infiltrate in the anterior chamber and 
vitreous cavity, but no hypopyon.  The aqueous humor was collected for culture 
and intravenous antibiotic (imipenem) and topical antibiotic (gatifloxacin and 
cefmenoxime) treatment was begun.  On the third day after IVB, however, the 
vitreous opacity became so dense that the optic disc could barely be seen and 
visual acuity declined to count fingers.  Urgent vitrectomy was performed with 
instillation of intravitreal antibiotics (vancomycin and ceftazidime); a sample of 
the aqueous humor and vitreous was collected for culture.  Both of these 
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cultures and the previously performed test on aqueous humor were negative for 
Gram-positive bacteria, Gram-negative bacteria, and fungi.  The inflammation 
subsided within a week and visual acuity returned to 1.0 in logMAR in both eyes 
by one month after the operation. 
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Discussion 
 
The present study consists of 14 consecutive cases of endophthalmitis 
after intravitreal injection of bevacizumab that had been derived from a single 
batch.  Because cultures of the aqueous humor and vitreous from five eyes with 
severe endophthalmitis were negative for bacteria and fungi, these eyes were 
believed to have a sterile endophthalmitis.  Except for two eyes with severe 
endophthalmitis, the visual acuity returned to that measured initially.  Although 
it is possible that inflammatory signs were not seen in those patients who did not 
return to the hospital for several days after examination on the day immediately 
after that of IVB injection, for analysis we classified the 19 cases in the present 
study into one of three groups: "no inflammation", "moderate inflammation", and 
"severe inflammation". 
Intravitreal injection of triamcinolone acetonide can also cause sterile 
endophthalmitis.  In the present study, however, triamcinolone acetonide could 
not have been the sole cause of the ocular inflammation because severe 
inflammation occurred in eyes that did not receive triamcinolone acetonide.  
Taban et al. have shown a possible association with prior history of uveitis in 
sterile endophthalmitis after intravitreal triamcinolone acetonide (IVTA).28  
However, no patient in the present study had a history of uveitis.  Pseudophakia 
is also a risk factor for sterile endophthalmitis after IVTA,29 but, because the lens 
status was not different among the three groups (i.e., "no inflammation", 
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"moderate inflammation", and "severe inflammation"), this was not a risk factor 
for ocular inflammation after injection of IVB in the present study. 
Because bevacizumab is a full-length humanized IgG antibody, 
repeated injection might increase the risk of sterile endophthalmitis.  However, 
in the study described herein, prior IVB did not affect the severity of ocular 
inflammation.  Recently, Stepien et al. reported a clustering of sterile 
endophthalmitis after IVTA that occurred during the same period at three clinical 
centers that were located very near to each other.30  They suggested that 
endotoxin in the same lot, or in lots produced close together, might have caused 
these cases of sterile endophthalmitis.  Wickremasinghe et al. have reported 19 
cases of acute severe intraocular inflammation after IVB treatment at six 
different clinical practices.  They also suggested the possibility that trace 
endotoxin contamination of the bevacizumab, contamination whose level was 
not sufficient to cause any sign when administered systemically,31 might have 
resulted in the intraocular inflammation.  Our 14 cases of sterile 
endophthalmitis caused by a single batch of bevacizumab seem to support 
these hypotheses.  The 14 cases in the present study might represent sterile 
endotoxin-induced uveitis, considering that five eyes were negative for culture 
and the inflammatory reaction in the remaining nine eyes subsided with steroid 
treatment. 
In summary, we have reported 14 consecutive cases of sterile 
endophthalmitis after intravitreal injection of bevacizumab that was derived from 
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a single batch.  Most of these cases developed inflammatory signs a few days 
after IVB injection.  All eyes, save two, had a return of visual acuity after 
treatment, including PPV, to that measured initially. 
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Figure Legend 
 
Visual acuity in logMAR immediately before intravitreal injection of bevacizumab 
(x-axis) and at the final examination one month after the injection (y-axis).  
Circles indicate eyes without ocular inflammation; triangles indicate eyes with 
moderate inflammation; reversed triangles indicate eyes with ocular 
inflammation severe enough to require pars plana vitrectomy. 

Table 1.  Patient Demographics 
 













1 89 L PCV 
IVTA 
PDT 
0 Cataract 0.70 0.52 None 
2 81 L RAP  1 Cataract 0.70 0.70 None 
3 79 L BRVO  1 PC-IOL 0.16 0.10 None 
4 59 L AMD PDT 0 Cataract 0.82 0.82 None 
5 77 
R AMD  2 Cataract 1.00 0.82 None 
L AMD  2 Cataract 0.30 0.52 Moderate 
6 77 R BRVO  2 Cataract 1.00 1.00 Moderate 
7 80 R AMD 
IVTA 
PDT 
0 Cataract 0.70 0.70 Moderate 
8 68 R BRVO  0 Aphakia 0.30 0.30 Moderate 
9 82 L AMD  4 Cataract 0.30 0.40 Moderate 
10 91 R AMD  0 PC-IOL 0.16 0.30 Moderate 
11 72 R PCV  5 Cataract 0.05 0.22 Moderate 
12 78 
R AS  2 PC-IOL 1.00 1.00 Moderate 
L AS  0 Cataract 0.05 0.05 Moderate 
13 84 
R RAP  5 PC-IOL 0.00 0.00 Severe 
L RAP  0 PC-IOL 1.00 0.82 Severe 
14 61 L mCNV  1 Cataract 0.52 1.10 Severe 
15 82 
R mCNV  1 PC-IOL 0.40 1.00 Severe 
L mCNV  4 PC-IOL 0.82 1.00 Severe 
PCV, polypoidal choroidal vasculopathy; RAP, retinal angiomatous proliferation; BRVO, 
branch retinal vein occlusion; AMD, age-related macular degeneration; AS, angioid 
streaks; mCNV, myopic choroidal neovascularization; IVB, intravitreal injection of 
bevacizumab; IVTA, intravitreal injection of triamcinolone acetonide simultaneously with 
IVB; PDT, photodynamic therapy three days after IVB; PC-IOL, posterior chamber 
intraocular lens; Pre VA, visual acuity immediately before IVB; Final VA, visual acuity at 
one month after IVB.














5 L 3 days    + + Steroid and antibiotics (topical)  
6 R 2 days  +  +  Steroid and antibiotics (topical)  
7 R 2 days    + + Antibiotics (topical)  
8 R 2 days  ++  ++  Steroid and antibiotics (topical)  
9 L 1 day     + Steroid and antibiotics (topical)  
10 R 7 days     + Antibiotics (topical)  
11 R 1 day + +  + ++ Steroid and antibiotics (topical and systemic)  
12 
R 3 days    ++ ++ Steroid and antibiotics (topical and systemic)  
L 3 days    ++ ++ Steroid and antibiotics (topical and systemic)  
13 
R 1 day + ++ + ++ +++ PPV Negative 
L 1 day + ++ + ++ +++ PPV Negative 
14 L 2 days + ++ + ++ +++ PPV Negative 
15 
R 1 day + ++  +++ +++ PPV Negative 
L 1 day + ++  +++ +++ PPV Negative 
AC cells, cellular infiltration into anterior chamber; Vit. Opacity, vitreous opacity; PPV, pars plana vitrectomy.  Anterior chamber cells 
were graded as follows; (+), 5-20 cells, (++), 20-50cells, and (+++) more than 50 cells per 1 x 1 mm slitbeam field.  Vitreous opacity 
was graded as follows; (+), retinal vessels are hazily visible, (++), optic nerve head is visible but border of the optic nerve head is quite 
blurry, and (+++), optic nerve head is obscure. 
